Covid-19 roundup: Mer­ck, Ridge­back drop new analy­ses for mol­nupi­ravir; Veru sub­mits EUA for an­tivi­ral treat­ment

As Mer­ck and Ridge­back look to make their Covid an­tivi­ral more com­pet­i­tive to Pfiz­er’s Paxlovid, the com­pa­nies pub­lished ad­di­tion­al da­ta from their Phase III tri­al eval­u­at­ing mol­nupi­ravir, oth­er­wise known as Lagevi­ro.

The tri­al in­ves­ti­gat­ed non-hos­pi­tal­ized adults with mild to mod­er­ate Covid-19 who were at high risk for pro­gress­ing to se­vere dis­ease. Re­sults showed the ex­plorato­ry end­points in­di­cat­ed that a low­er pro­por­tion of Lagevi­ro-treat­ed par­tic­i­pants had an acute care vis­it or a Covid-19-re­lat­ed acute care vis­it ver­sus place­bo-treat­ed par­tic­i­pants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER